MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
See also 4F-MDMB-BINACA 6-Bromopravadoline ADB-PINACA ADB-5'F-BUTINACA ADB-5'Br-BUTINACA ADB-5'Br-PINACA ADSB-FUB-187 MDMB-BINACA MDMB-5'Br-4en-PINACA
References